



# The Home Health Administration Program

Making Somatuline<sup>®</sup> Depot (lanreotide) Injection treatment more accessible for your eligible\* patients

## INDICATION

Somatuline<sup>®</sup> Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who had an inadequate response to or cannot be treated with surgery and/or radiotherapy.

## Select Important Safety Information

### CONTRAINDICATIONS

Somatuline is contraindicated in patients with hypersensitivity to lanreotide. Allergic reactions (including angioedema and anaphylaxis) have been reported following administration of lanreotide.

### WARNINGS AND PRECAUTIONS

- Cholelithiasis and Gallbladder Sludge: Somatuline may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed

\*Patient eligibility restrictions available on next page.

*Please see additional Important Safety Information throughout and full Prescribing Information in pocket.*

# The Home Health Administration Program

## **Our nurses help keep your eligible patients connected to treatment**

As a healthcare provider who recognizes the benefits Somatuline® Depot (lanreotide) Injection can offer your patients, you understand the importance of proper administration of every injection. But you also know that visits to the office sometimes conflict with your patients' lifestyles.

Created for patients who find it difficult to make it to the office regularly, the Home Health Administration Program ensures your eligible patients receive Somatuline Depot treatment from a registered nurse without having to leave their homes.

The program is not intended to replace regular office visits. To keep you up-to-date, you will be sent regular reports to confirm that your patients receive Somatuline Depot as you have prescribed.

## **Enrolling your eligible patients**

Getting your patients started with the program is simple:

1. As the prescriber, you evaluate each of your patients and decide who may be appropriate to receive injections at home
2. Complete a Somatuline Depot IPSEN CARES™ Enrollment Form and check the box indicating that the Home Health Administration Program is requested. You can download the form or enroll your patient online at [IPSENCARES.com](https://IPSENCARES.com)
3. IPSEN CARES verifies the patient's benefits and program eligibility

## **Select Important Safety Information (continued)**

### **WARNINGS AND PRECAUTIONS (continued)**

- **Hypoglycemia or Hyperglycemia:** Pharmacological studies show that Somatuline, like somatostatin and other somatostatin analogs, inhibits the secretion of insulin and glucagon. Blood glucose levels should be monitored when Somatuline treatment is initiated, or when the dose is altered, and antidiabetic treatment should be adjusted accordingly
- **Thyroid Function:** Slight decreases in thyroid function have been seen in acromegalic patients during treatment, though clinical hypothyroidism is rare (<1%). Thyroid function tests are recommended where clinically indicated

***Please see additional Important Safety Information throughout and full Prescribing Information in pocket.***



## Coordinating at-home administration

IPSEN CARES coordinates the details of the Home Health Administration Program, including:

### • Shipments of Somatuline Depot

- Once a patient's benefits are verified, an IPSEN CARES Patient Access Specialist manages the shipment of Somatuline Depot via Specialty Pharmacy
- Specialty Pharmacy then sends Somatuline Depot directly to the patient's home

### • Assignment of a Home Health Nurse (HHN)

- Each patient is assigned an HHN who contacts the patient, confirms the date of the first injection, and schedules subsequent visits with the patient

### • Notifications of successful administration

- After each visit, the HHN will send a fax to your office to confirm administration of the product to the patient

## Determining your patients' eligibility

The Home Health Administration Program is an additional support offering of IPSEN CARES available at your direction for all eligible patients prescribed Somatuline Depot.

- A physician must prescribe Somatuline Depot to be administered by Home Health Administration for the patient
- The program is available to most patients covered by commercial insurance plans
- Patients are not eligible if prescriptions are paid in part or full by any state- or federally funded programs, including, but not limited to, Medicare or Medicaid, VA, DOD, or TRICARE
- Residents of Massachusetts, Michigan, Minnesota, and Rhode Island are not eligible

## Select Important Safety Information (continued)

### WARNINGS AND PRECAUTIONS (continued)

- **Cardiac Abnormalities:** Somatuline may decrease heart rate. In cardiac studies with acromegalic patients, the most common cardiac adverse reactions were sinus bradycardia, bradycardia, and hypertension. In patients without underlying cardiac disease, Somatuline may lead to a decrease in heart rate without necessarily reaching the threshold of bradycardia. In patients suffering from cardiac disorders prior to treatment, sinus bradycardia may occur. Care should be taken when initiating treatment in patients with bradycardia



For more information, visit [IPSENCARES.com](http://IPSENCARES.com)  
or call (866) 435-5677 between 8:00 AM and  
8:00 PM Monday through Friday.

## Select Important Safety Information (continued)

### WARNINGS AND PRECAUTIONS (continued)

- Drug Interactions: The pharmacological gastrointestinal effects of Somatuline may reduce the intestinal absorption of concomitant drugs. Concomitant administration of Somatuline may decrease the relative bioavailability of cyclosporine and may necessitate the adjustment of cyclosporine dose to maintain therapeutic levels

### ADVERSE REACTIONS

The most common adverse reactions (incidence >5%) were diarrhea (37%), cholelithiasis (20%), abdominal pain (19%), nausea (11%), injection-site reactions (9%), constipation (8%), flatulence (7%), headache (7%), arthralgia (7%), vomiting (7%), and loose stools (6%).

### USE IN SPECIFIC POPULATIONS

Patients with moderate and severe renal impairment or moderate and severe hepatic impairment: Initial dose is 60 mg every 4 weeks.

You may report suspected adverse reactions to FDA at 1-800-FDA-1088 or to Ipsen Biopharmaceuticals, Inc. at 1-888-980-2889.

***Please see additional Important Safety Information throughout and full Prescribing Information in pocket.***



Somatuline Depot is a registered trademark of Ipsen Pharma S.A.S.  
IPSEN CARES is a trademark of Ipsen S.A.S.

©2015 Ipsen Biopharmaceuticals, Inc. November 2015. ICA-US-000002